FAMILIAL CHYLOMICRONEMIA SYNDROME
Clinical trials for FAMILIAL CHYLOMICRONEMIA SYNDROME explained in plain language.
Never miss a new study
Get alerted when new FAMILIAL CHYLOMICRONEMIA SYNDROME trials appear
Sign up with your email to follow new studies for FAMILIAL CHYLOMICRONEMIA SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shows promise for rare fat disorder in extended trial
Disease control OngoingThis study tests a drug called olezarsen in people with familial chylomicronemia syndrome (FCS), a rare genetic condition that causes extremely high blood fat levels. The goal is to see if the drug can safely lower triglycerides over the long term. About 60 participants who compl…
Matched conditions: FAMILIAL CHYLOMICRONEMIA SYNDROME
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 08:09 UTC
-
New hope for rare fat disorder: safety trial launches for olezarsen
Disease control OngoingThis study tests the safety of a new drug called olezarsen in 24 people with familial chylomicronemia syndrome (FCS), a rare condition that causes extremely high blood fats. Participants have already been treated with a similar drug, volanesorsen. The study monitors for side effe…
Matched conditions: FAMILIAL CHYLOMICRONEMIA SYNDROME
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New shot aims to tame dangerous fat levels in blood
Disease control OngoingThis study tests a new medicine called RN0361 in healthy adults and people with very high triglycerides (a type of fat in the blood). The goal is to see if a single dose is safe and can lower fat levels. About 108 participants will receive either the drug or a placebo. The study …
Matched conditions: FAMILIAL CHYLOMICRONEMIA SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: Ikaria Bioscience Pty Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC